CB, cannabinoid; DMSO, dimethyl sulphoxide; DSE, depolarization induced suppression of excitation; ENS, enteric nervous system; EPSC, excitatory postsynaptic current; GI, gastrointestinal; IBS, irritable bowel syndrome; i.p., intraperitoneal.
INTRODUCTION
The endogenous cannabinoid system consists of cannabinoid (CB) 1 and CB 2 receptors, endogenous cannabinoid ligands and the biosynthetic and degradative enzymes for these endocannabinoids (Pertwee et al., 2010; Di Marzo & De Petrocellis, 2012; Piomelli, 2014) . The endocannabinoid system is importantly involved in the regulation of gastrointestinal (GI) motility (Aviello et al., 2008; Izzo & Sharkey, 2010; Abalo et al., 2012; Nasser et al., 2014) . CB 1 receptors are present within the enteric nervous system (ENS) and CB 1 receptor activation reduces the release of neurotransmitters, notably acetylcholine, to limit excitatory neurotransmission in the ENS (Duncan et al., 2005; Izzo et al., 2010; Hons et al., 2012) .
Activation of the CB 1 receptor slows motility throughout the GI tract and reduces intestinal and colonic contractility in animal models (Aviello et al., 2008; Izzo et al., 2010; Abalo et al., 2012; Nasser et al., 2014) .
Only a few clinical studies have investigated the effects of cannabinoids on GI motility. In healthy volunteers, orally administered Δ 9 -tetrahydrocannabinol (dronabinol) slows gastric emptying and reduces colonic motility, but has limited effects on small intestinal motility (McCallum et al., 1999; Esfandyari et al., 2006; Esfandyari et al., 2007) . In patients with irritable bowel syndrome (IBS), Wong et al. (2011 Wong et al. ( , 2012 variably reported rather modest effects of dronabinol on fasting colonic motility in patients with diarrhea-predominant and alternating forms of IBS (Wong et al., 2011) , and in a second study, reported no effects on gastric, intestinal and colonic transit in patients with diarrhea-predominant IBS (Wong et al., 2012) .
Oral Δ 9 -tetrahydrocannabinol is rapidly metabolized and severely limited as a therapeutic
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agent by unwanted psychotropic and neurological "side-effects" (Borgelt et al., 2013; Volkow et al., 2014) . Therefore, the opportunity to translate the potential of cannabinoids for the treatment of GI motility disorders such as diarrhea-predominant IBS, which affects millions around the world, have not been fully realized. The limitations of traditional cannabinoids are not restricted to GI disorders, hence considerable efforts have been made to develop peripherally restricted cannabinoid ligands where the beneficial actions can be attained in the absence of central side-effects (Kunos et al., 2009; Chorvat, 2013) . Many of these compounds have been found in animal studies to have very favourable activity profiles for the potential treatment of a range of disorders, including disturbed GI motility (Cluny et al., 2010a; Cluny et al., 2010b; Yu et al., 2010; Tam et al., 2012) .
A covalent cannabinoid agonist, AM841 was recently described (Picone et al., 2005; Pei et al., 2008; Hurst et al., 2010; Szymanski et al., 2011) . AM841 interacts with the CB 1 receptor binding site through a structural motif shared by all cannabinoid ligands. It subsequently irreversibly attaches to a single specific amino acid within that site, to activate the CB 1 receptor.
Because of its unique chemical properties and it's demonstrated effect in reducing symptoms
of experimental colitis in mice (Fichna et al., 2014) , we examined this compound to assess its potential as a novel cannabinoid receptor ligand for use in physiological and pathophysiological in vivo studies.
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Electrophysiology
All experiments were performed on isolated autaptic neurons (Straiker & Mackie, 2005; Straiker et al., 2012) . Whole cell voltage-clamp recordings from autaptic neurons were carried out at room temperature using Axopatch 200A amplifier (Axon Instruments, Burlingame, CA).
The extracellular solution contained (in mM) 119 NaCl, 5 KCl, 2.5 CaCl 2 , 1.5 MgCl 2 , 30 glucose, and 20 HEPES. Continuous flow of solution through the bath chamber (1-3 ml/min) ensured rapid drug application and clearance. Drugs were prepared as stock, then diluted into extracellular solution at their final concentration and used on the same day. Drugs dissolved in DMSO were used at a final DMSO concentration of < 0.1%. Recording pipettes of 1. 8-3 M were filled with (in mM) 121.5 KGluconate, 17.5 KCl, 9 NaCl, 1 MgCl 2 , 10 HEPES, 0.2 EGTA, 2
MgATP, and 0.5 LiGTP. Access resistance was monitored and only cells with stable access resistance were included for data analysis. Data were acquired at a sampling rate of 5 kHz.
Stimulus protocols to elicit DSE have been described previously (Straiker et al., 2005) .
Trafficking studies
Cell surface receptors were measured as previously described (Daigle et al., 2008) . For internalization, cells were incubated with the indicated agonist for the indicated times, fixed, and cell surface receptors determined. For the recycling assay, cells were treated with agonist for 30 min, and then treated with antagonist for the indicated times, before fixation and determination of cell surface receptors. For the recycling assays, cells were treated with 70μM cycloheximide after the initial internalization to prevent the synthesis of new CB 1 receptors.
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IN VIVO STUDIES
Animals for behavioural and GI studies
5-7 weeks old male CD1 mice (26-40 g) as well as 9-24 weeks old male CB 1 -/-and CB 2 -/-mice (23-46 g) on a CB57BL/6 background and 6-15 weeks old male C57BL/6 wild type mice (CB 1 +/+ ; 18-34g) were used. The C57BL/6 and the CD1 mice were obtained from Charles River (Montreal, PQ, Canada) and the CB 1 -/-, CB 2 -/-and CB 1 +/+ were bred at the University of Calgary mouse breeding facility as previously described (Cluny et al., 2009 ). Mice were housed at a constant temperature of 22°C and kept at a constant photoperiod (12:12-h light-dark cycle) in plastic cages on sawdust with access to standard laboratory chow and tap water ad libitum. The mice were allowed to acclimate for at least 1 week. All drugs for the in vivo studies were dissolved in Tween 80 (1%) and dimethyl sulphoxide (DMSO, 2%) and then further diluted in 0.9% saline up to the final concentration. These experiments were approved by the University of Calgary Animal Care Committee and were performed in accordance with guidelines established by the Canadian Council of Animal Care.
Spontaneous locomotor activity
Locomotor activity was measured using an infrared beam activity monitor (Columbus Instruments, Columbus, OH, USA) as previously described (Cluny et al., 2010a) . C57BL/6 mice were individually placed in the apparatus (at the same location) and the counts were recorded for 10 min. The apparatus was cleaned with 70% EtOH between subjects. Mice underwent a trial in the morning (between 9am-12pm) to acclimatize them to the locomotor activity box and Accepted Article the experiment was conducted in the afternoon (between 1-4pm) of the same day. Mice were injected intraperitoneally (i.p.) with either AM841 (0.1 or 1.0 mg/kg), WIN55,212-2 (1 mg/kg) or vehicle (2% DMSO, 1% Tween 80 in physiological saline) 20 min prior to being placed in the locomotor activity box.
Thermoregulation
Body temperature was measured using silicone-coated data loggers (SubCue, Calgary, Canada) that were implanted surgically into the abdomen of CB 1 -/-and CB 1 +/+ mice under halothane anesthesia as previously described (Duncan et al., 2013) . We used CB1 -/-in this assay to further validate the specificity of AM841 in vivo. Mice were allowed to recover for 1 week, injected with AM841 (0.1 mg/kg; i.p.) and sacrificed 24 hr later. The data logger was removed and the data retrieved and analyzed using SubCue Analyzer software. Core body temperature was taken every 5 min from 100 min prior to 400 min post agonist injection. The maximum decrease in body temperature from baseline (-100 to 0 min) was determined. Since the effects of cannabinoids on core body temperature, including WIN55,212-2, have been well documented additional "positive controls" were not performed (Dalle Carbonare et al., 2008; Wallace et al., 2009; Wiley et al., 2014) .
Analgesia
Mice were treated with vehicle in the morning and 20 min later assessed for pain (nociceptive) threshold using a thermal analgesia meter (Columbus Instruments, Columbus, OH, USA) set at 55 o C as previously described (Duncan et al., 2013 The difference between the responses at both time points was determined and the differences in hot plate latency compared by paired t-test.
Upper GI transit
Upper GI transit experiments were performed as described in detail previously (Cluny et al., 2009) . Briefly, twenty min after i.p. administration of drugs (or vehicle) 0.2 ml of 5% Evans blue suspension in 5% gum Arabic was given by gastric gavage. 15 min later animals were sacrificed by cervical dislocation and the total intestine was immediately removed. The distance travelled by the colored marker was measured and expressed as percentage of the total length of the small intestine from the pylorus to the caecum. In separate experiments the effect of antagonists (AM251 (0.5-5 mg/kg) and AM630 (1-5 mg/kg)) were tested on AM841 (0.1 mg/kg).
Mice received antagonists 20 min before AM841. The effect of AM841 (1 mg/kg) was additionally tested in CB 1 -/-and CB 2 -/-mice and their wildtype littermates.
Colonic propulsion
Distal colonic propulsion was measured using the method first reported by Raffa et al. (Raffa et al., 1987) . Briefly, 20, 120 and 220 min after i.p. or oral administration of drugs (or vehicle), a plastic bead (2.5 mm) was inserted 3 cm into the distal colon of each mouse using a silicone pusher. The time to expulsion of the bead was determined for each animal three times (at Accepted Article 100min intervals) and then the mean of these three time points was calculated. A higher mean expulsion time indicates a stronger delay of colonic propulsion. In separate experiments the effect of AM251 (2 mg/kg) and AM630 (1 mg/kg) was tested on AM841 (0.1 mg/kg). The effect of AM841 (1 mg/kg) was additionally tested in CB 1 -/-and CB 2 -/-mice and their wildtype littermates.
Stress enhanced upper GI transit
Previous experiments from our lab have shown that moving group housed mice from their home cage individually into a transparent plastic cage without a sawdust floor or bedding, termed 'novel environment' accelerated upper GI transit time (Cluny et al., 2009) . Mice were injected with AM841 (0.0001 -10 mg/kg, i.p.) or vehicle and placed individually into the novel environment described above. Other mice received an i.p. vehicle injection and were returned to their home cage, with their cage mates, and served as controls for baseline upper GI transit.
Twenty min later mice were gavaged with 0.1 ml of a charcoal marker (10% charcoal suspension in 5% gum Arabic) and upper GI transit was measured 15 min after the gavage as detailed above.
Stress enhanced colonic transit
Mice were injected with AM841 (0.01mg/kg, i.p.) or vehicle and 20 min later transferred from their home cage (group housed 3-4/cage) into individual transparent plastic cages (novel environment) without bedding or wire lid. Mice did not receive food or water during the 1 hr of monitoring. Fecal pellets were removed from the cage every 15 min for 1 hr. Pellet number was recorded. Some mice were trained by mock injecting them (abdominal needle poke) and then 20min later placing them into the novel environment for 1 hr each day for 3 days prior to the experiment. The mice that did not receive training are referred to as "stressed" while those that were exposed to the novel environment repeatedly are referred to as "trained".
BRAIN PENETRATION STUDIES
Animals and dosing protocol
Procedures were approved by the Animal Care Committee of Northeastern University and conform to the Guidelines of the National Institutes of Health on the Care and Use of Animals.
Male CD1 mice (Charles River Laboratories, Willmington, MA, USA) were acclimated to vivarium conditions for one week prior to experimentation; water and food were provided ad libitum.
On the experimental day, the mice (25-30 g) were administered with AM841 (1 mg/kg i.p. in a dosing volume of 0.2 mL emulphor:ethanol:saline (1:1:18) with 3% DMSO).
Collection and storage of biological samples
Samples were taken at various time points: 2 min to 8 hr after i.p. administration. Animals were sacrificed by cervical dislocation followed by decapitation. Plasma and brain tissue were flash frozen in liquid nitrogen and stored at -80°C until analysis (Rahn et al., 2011) .
Sample Extraction and LC-MS/MS analysis
The tissue sample extraction procedure was a modified version of the Folch extraction (Folch et al., 1957; Rahn et al., 2011) . Calibration curves were constructed from the ratios of the peak areas of the analytes versus the internal standard in extracted standards made in homogenized purchased mouse brain or plasma (Bioreclamation.com).
An Agilent 1100 series HPLC was the front end for a Thermo Finnigan Quantum Ultra triple quad mass spectrometer equipped with a Phenomenex Gemini C18 column (2 x 50 mm, 5m). The mobile phases used were 0.1% formic acid in water (A) and 0.1% formic acid in methanol (B) in a 9 min gradient. AM841 was ionized in APCI+ and detected in SRM mode. Non-compartmental analysis was conducted on the plasma and brain samples via the "sparse data model" using
WinNonlin software (Pharsight Corp; Mountain View, CA, USA).
CB 1 mRNA EXPRESSION
CB 1 mRNA expression in ileal and hypothalamic samples of non-stressed and novelenvironment stressed CD1 mice was compared using real-time PCR as described previously (Bashashati et al., 2012) . RNA was extracted using the QIAGEN RNeasy Plus Mini Kit (Qiagen, Mississauga, ON, Canada) and a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) was used for generating cDNA. The rodent glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe (VIC), as the internal reference, and TaqMan Gene Expression assay kit for CB 1 (Mm00432621_s1), both from Applied Biosystems, were used for real-time PCR performed using ABI Prism 7000 Sequence Detection System (Applied
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Biosystems). Results were analyzed by ABI Prism 7000 SDS (Applied Biosystems) and presented as relative quantification values.
Statistics
Prism 6 for Windows (version 6.03, GraphPad Software, La Jolla, CA, USA) was used for analysis of the data. T-tests were performed between 2 groups and one or two way analysis of variance (ANOVA) followed by appropriate post-hoc tests were used for multiple groups. P values < 0.05
were considered statistically significant. Data are presented as mean ± SEM. Fig. 1) was originally described as an irreversible covalent cannabinoid ligand (Picone et al., 2005) . We first assessed if AM841 behaves as a covalent ligand using two model biological assay systems in vitro. We then compared AM841 to the commonly used CB receptor ligand WIN55,212-2 in in vivo studies.
RESULTS
AM841 (
AM841 irreversibly inhibits synaptic transmission and occludes depolarization-induced suppression of excitation (DSE)
We assessed whether AM841 behaved as irreversible cannabinoid ligand using a wellcharacterized in vitro model system that possess endogenous cannabinoid signaling, autaptic cultures of hippocampal neurons (Sullivan, 1999; Straiker et al., 2005) . In autaptic cultures of hippocampal neurons, treatment with AM841 (100 nM) substantially and potently inhibited EPSCs ( Fig. 2A-B) , with an EC 50 of 6.8 nM. This inhibition was not reversed by treatment with the CB 1 receptor antagonist SR141716 ( Fig. 2A-C 2G ). In the presence of AM841 (100 nM) or WIN55,212-2 (100 nM) CB 1 receptors were rapidly internalized (Fig. 2H) . However, while CB 1 in the WIN55,212-2-treated cells rapidly recycled to the cell surface after treatment with SR141716 (100 nM), no recycling was evident in the AM841-treated cells, even after 120 min, by which time most of the CB 1 receptors in WIN55,212-2-treated cells had returned to the cell surface (Fig. 2H) . These results suggest that AM841 remains bound to CB 1 receptors even in the presence of SR141716, preventing recycling of the receptors to the cell surface.
AM841 behaves as a peripherally restricted CB 1 receptor agonist in vivo
When administered to mice, AM841 did not produce the obvious behavioural effect typically associated with CB 1 receptor agonists, reduced spontaneous locomotor activity. We therefore
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systematically assessed three parameters of the CB tetrad test in detail (Little et al., 1988): (i) spontaneous locomotor activity (hypomotility) (ii) analgesia and (iii) hypothermia. We first assessed spontaneous locomotor activity in mice treated with AM841 (0.1 or 1 mg/kg), and WIN55,212-2 (1 mg/kg). These doses were chosen based on preliminary studies. AM841
produced no significant reduction in spontaneous locomotor activity, whereas WIN55,212-2 significantly reduced locomotor activity (Fig. 3A) . We next assessed the latency on a hotplate to paw withdrawal after injection of the test compound, compared to the time taken to withdrawal after vehicle injection. Analgesia, observed as an increase in latency, was clearly observed after treatment with WIN55,212-2 (1 mg/kg), but not with AM841 (0.1 mg/kg) ( Fig.   3B ). Finally, we assessed the thermoregulatory effects of AM841 in CB 1 +/+ and CB 1 -/-mice over a 6-7h time frame (Fig. 3C ). AM841 caused a transient stress-induced hyperthermia, but had no lasting effect on core body temperature in either group of animals. Taken together, these data suggest that AM841 is not centrally active when acutely administered in vivo.
Intraperitoneal AM841 is peripherally restricted
These results led us to assess the brain penetration of AM841 after an intraperitoneal injection.
Animals were administered AM841 (1 mg/kg, i.p.) and the brain and plasma levels were measured over 8h. The AM841 standard curve was linear with a regression value of >0.996 and the extraction efficiencies were greater than 85% (plasma) and 83% (brain homogenate). The plasma area under the curve for AM841 was 3.75 ± 0.50 min*µg/mL and the brain 0.20 ± 0.02 min*µg/mL, giving a ratio of 0.05. By comparison brain penetrant cannabinoids have ratios of 1 or more (Dyson et al., 2005; Rahn et al., 2011; Adam et al., 2012) .
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AM841 is a potent and efficacious CB 1 receptor agonist in the GI tract in vivo
We next examined the effects of AM841 compared to WIN55,212-2 in inhibiting upper GI transit in the mouse. In vehicle-treated animals the marker used to determine intestinal transit traveled 84.2 ± 2.4 % of the intestinal length in 15 min. AM841 potently inhibited transit to a maximum of about 70% of the level seen in vehicle-treated animals (Fig. 4A) . The EC 50 of this response was 0.004 mg/kg. WIN55,212-2 was far less potent than AM841 (Fig. 4A) . The effects of AM841 (1 mg/kg) were abolished in CB 1 -/-mice, and virtually identical in CB 2 -/-and wild type mice (Fig. 4B ). They were also abolished by pretreatment with AM251 (5 mg/kg) and unaffected by AM630 (5 mg/kg) (Fig. 4C ).
We then examined the magnitude and duration of the effects of AM841 and WIN55,212-2 in inhibiting colonic transit. AM841 potently inhibits colonic bead expulsion with an EC 50 of 0.03 mg/kg (Fig. 5A) . The maximum magnitude of the effects -a five-six fold slowing of colonic transit (0.1 mg/kg) -was comparable to that observed with WIN55,212-2 (3 mg/kg), 20min
after administration (Fig. 5B) . AM841 is more potent than WIN55,212-2 (Fig. 5A, B) . The effects of AM841 were completely abolished in CB 1 -/-mice, and virtually identical in CB 2 -/-mice compared to wild type controls (Fig. 5C ). They were abolished by AM251 (2 mg/kg) and unaffected by AM630 (1 mg/kg) (Fig. 5D ).
AM841 is more potent in vivo in acutely-stressed mice and reduces stress-enhanced intestinal
Accepted Article and colonic motility
Finally, because of the properties of AM841, we examined whether we could use this compound in an assay of dysmotility: to correct acute stress-induced enhancement of intestinal and colonic transit.
Upper GI transit was significantly increased in the stressed, compared to the non-stressed mice (non-stressed: 49.5 ± 2.6%; stressed: 56.2 ± 2.6% of intestinal length; p<0.05, n=12). AM841
(0.0001 -10.0 mg/kg) dose-dependently slowed upper GI transit in stressed and non-stressed animals ( Fig. 6A) . Interestingly, the EC 50 was 0.001 mg/kg in the stressed animals, which is slightly lower than that observed in non-stressed animals. A dose of AM841 that slightly slowed upper GI transit in normal mice (0.001 mg/kg), significantly slowed transit in the stressed animals (Fig. 6B) . The effects of AM841 on upper GI transit were abolished by AM251
(5 mg/kg) but not by AM630 (5 mg/kg) (Fig. 6B) . Stressed rodents show an enhanced output of fecal pellets (Martinez et al., 1997; Million et al., 2007) . The cumulative fecal pellet output at 15, 30, 45 and 60 min was 1.1±0.4, 1.8±0.6, 2.8±0.9 and 3.1±0.9 respectively in trained mice vs 3.0±0.5, 3.7±0.7, 4.8±0.9 and 6.0±0.9 respectively in stressed mice (n=10-11) with the peak response occurring in the first 15 min observation period. AM841 (0.01 mg/kg) completely normalized the enhanced fecal pellet output observed in acutely-stressed mice (Fig. 6C ).
Acute stress does not change CB1 mRNA expression in the GI tract
Since AM841 appeared to have a greater potency in stressed mice, we examined CB 1 mRNA levels measured by real-time PCR. CB 1 mRNA levels were not significantly different in the ileum
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(or hypothalamus) of novel-environment stressed mice compared to non-stressed animals (data not shown).
DISCUSSION
Here we describe the actions of a novel covalent cannabinoid agonist AM841 (Picone et al., 2005) . In vitro, AM841 behaves as an irreversible CB 1 receptor ligand, as expected from its chemical properties. AM841 potently reduces GI motility through an action on CB 1 receptors in the small and large intestine under physiological conditions. It appears that AM841 is even more potent under conditions of acute stress, and was shown to normalize accelerated GI motility under these conditions. This compound behaves as a peripherally-restricted ligand,
showing very little brain penetration and no characteristic CB 1 receptor-mediated effects in the central nervous system. These findings extend the observations demonstrating that AM841 is effective in suppressing experimentally-induced colitis in mice (Fichna et al., 2014) .
AM841 is a classical cannabinoid analogue with an isothiocyanate group at the last carbon of its dimethylheptyl chain (Picone et al., 2005) . AM841 binds to the helix 6 of the CB 1 and CB 2 receptor, through different binding motifs (Picone et al., 2005; Pei et al., 2008; Szymanski et al., 2011) . For both receptors, the functional potencies of this ligand exceeded by 20-to 50-fold that of structurally-related noncovalent analogues, and so AM841 was designated as a "megagonist" (Szymanski et al., 2011; Makriyannis, 2014) .
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Building on our understanding of the chemical properties of AM841, we first undertook some in vitro electrophysiological and receptor trafficking studies to confirm that it behaved as expected in these biological assay systems. Here we found that AM841 behaved as a very potent (low nM) agonist which was not displaceable from the receptor after binding, using the inverse agonist SR141716, in contrast to the classic ligand WIN 55,212-2, which is readily displaced. Activation of CB 1 receptors by agonists often leads to CB 1 receptor internalization (Hsieh et al., 1999) . Incubation of rCB 1 expressing HEK cells with AM841 caused a dosedependent loss of cell surface CB 1 receptor immunoreactivity. If agonist application is brief and followed by antagonist, internalized CB 1 receptors can be recycled back to the cell surface (Hsieh et al., 1999) . Presumably this occurs because after the antagonist displaces the agonist, the receptor is dephosphorylated and recycled back to the cell surface (Moore et al., 2007) .
The absence of receptor recycling following antagonist treatment suggests that AM841 remains covalently bound to the CB 1 receptor, even after internalization.
When animals were injected with AM841 it was immediately apparent that they behaved similar to vehicle controls and no adverse events or outcomes were observed following treatment. This finding led us to investigate the brain penetration of AM841 and to conduct behavioural tests to assess if this ligand displayed any classical cannabinoid actions, namely, hypothermia, analgesia and/or hypomotility. In no case did we observe that AM841 exhibited the classical CNS actions of a CB 1 receptor agonist and this we attribute to its demonstrated inability to access the brain in significant quantities. One possible explanation for this observation is that the compound is a substrate for one or both the multidrug resistance
proteins (MRP1 and MRP2) as has been reported by the naturally occurring phenethyl isothiocyanate (Ji & Morris, 2005; Morris & Dave, 2014) . Similar mechanisms have also recently been proposed for the exclusion of other peripherally restricted cannabinoid ligands (Pryce et al., 2014) . However, these authors noted that the strains of mice we used have polymorphic cannabinoid drug pumps that lack functionality (Pryce et al., 2014) . If this is the case, then other pumps or different exclusion mechanisms might exist for AM841. This has to be determined in future studies.
Having the properties of a peripherally-restricted ligand, makes AM841 a very interesting molecule for studies of the GI tract. The endocannabinoid system regulates GI motility, but investigations of the actions of cannabinoids in vivo are frequently confounded by central effects of these drugs. Here we have isolated the actions to the periphery and demonstrate that AM841 is an efficacious and highly potent agonist of CB 1 receptors. Indeed, these results demonstrate the remarkable ability of AM841 to slow down transit with an EC 50 in the small intestine around 4 µg/kg. In the colon, the apparent potency is about 10 fold lower. In contrast, the potency of WIN55,212-2 does not seem to change much between these gut regions, although in both cases it is far less potent. It is not completely clear why this should be the case. In the colon, we were able to use a lower dose of AM251 to block the effects of AM841 than were required to block small intestinal transit (2 mg/kg vs 5 mg/kg). These data suggest that in the colon there is a lower effective receptor density on the enteric nerves than in the ileum. However, that has yet to be determined experimentally. Alternatively, the CB 1 receptor in the colon might be constitutively desensitized or in a state of inactivation to a greater extent Accepted Article than the ileum, due to a higher endocannabinoid tone in that region of the gut. Tonically, released endocannabinoids are present throughout the GI tract and cannabinoid "tone" has been reported in both the small and large intestine (Pertwee, 2001; Izzo et al., 2010; Storr et al., 2010) , but the relative endocannabinoid tone between these regions of gut has never been compared. As mentioned above, CB 1 receptors are found on cholinergic nerves of the ENS and reduce the release of acetylcholine (Duncan et al., 2005; Izzo et al., 2010) . The proportion of cholinergic and non-cholinergic nerves in the ileum and colon differs along the mouse GI tract, with much higher proportion being non-cholinergic in the colon (De Man et al., 2002; Mule et al., 2007; Baldassano et al., 2009; Bashashati et al., 2012) . Whether this also somehow influences the results of these in vivo transit studies remains to be determined. In the present study we still observed an effect of AM841 on colonic propulsion 3 hr after injection in control mice. Future investigations should examine the duration of action of a covalent ligand, like AM841, under both physiological and pathophysiological conditions and the potential consequences of irreversible agonism.
AM841 has been used previously as a high potency ligand to investigate the role of CB receptors in colitis (Fichna et al., 2014) . Here, it was given by the same route of i.p.
administration and was found to block the development of colitis, albeit with a slightly lower potency than was observed for colonic transit in the current study. Interestingly, the effects of AM841 were found to be mediated by both CB 1 and CB 2 receptors in this pathophysiological condition (Fichna et al., 2014) , whereas for GI motility under the conditions of our studies AM841 acted only on CB 1 receptors. In this study, AM841 was compared to another Accepted Article peripherally-restricted compound CB13 (Dziadulewicz et al., 2007) , which was not able to block colitis following i.p. administration. CB13 (aka SAB378 (Dziadulewicz et al., 2007; Cluny et al., 2010a) ) was shown by us to reduce motility via CB 1 receptors to a similar extent as seen for AM841 in the current study (Cluny et al., 2010a) . This suggests that the covalent nature or the potency of AM841 seems to confer some unique properties on AM841 since it is clearly peripherally restricted and yet blocks colitis and inhibits motility.
Acute stress leads to an acceleration of small intestinal and colonic transit (Tache & Perdue, 2004) . Under these conditions we observed that AM841 was effective at slowing the accelerated transit and remarkably, a dose of AM841 without significant effect in normal animals now significantly slowed small intestinal transit and normalized colonic transit. These findings occurred without an alteration in receptor mRNA expression in the GI tract. Previous studies from our group showed in a similar paradigm that the endogenous lipid signaling molecule oleoylethanolamide was also able to reverse accelerated small intestinal motility with a higher potency than under physiological conditions (Cluny et al., 2009 ). The receptor mediating this effect was not identified, but was not the CB 1 receptor. Nevertheless, it is tempting to speculate that stress leads to an alteration in lipid / cannabinoid signaling in the GI tract as an adaptive mechanism to slow small intestinal motility.
Our findings of enhanced fecal pellet output are very similar to those previously reported by Million and colleagues (Million et al., 2007) . They showed that acute novel-environment stress leads to enhanced fecal pellet output whose magnitude and duration are virtually identical to Accepted Article what we observed. This effect is mediated by corticotrophin releasing factor signaling pathways and cholinergic neurons of the myenteric plexus. Consistent with this model, we
propose that AM841 is acting on CB 1 receptors on myenteric cholinergic neurons to reduce transmission and slow the gut. Our in vivo studies cannot pinpoint the exact site of action, which could be through inhibiting presynaptic neurotransmitter release or prejunctional release or both.
Currently, there are very limited treatment options for functional GI disorders, in which motility is altered leading to severe symptoms (Camilleri, 2013) . Cannabis is frequently used to relieve the symptoms of these disorders. However, the unwanted psychotropic effects limit its usefulness as a therapeutic agent. Here we have discovered a class of molecule with potential beneficial actions on abnormally accelerated GI motility that lacks any central actions. Because of its high potency, efficacy and duration of action, it seems well suited to further development as therapeutic agent.
In summary, AM841 is a novel covalent cannabinoid agonist that behaves as an irreversible CB 1 receptor ligand in vitro. AM841 shows little brain penetration and so behaves as a peripherally restricted cannabinoid ligand. AM841 potently reduces GI motility in vivo by acting at CB 1 receptors in the small and large intestine. When GI transit is accelerated under conditions of acute stress, AM841 was able to normalize it. These data suggest that this novel CB ligand represents a new class of potential therapeutic agents for the treatment of GI disorders. There was a rapid increase in body temperature on initial injection due to the acute stress of injection that was seen in both groups of mice. AM841 had virtually no effect on core body temperature over ~7h. Inset in C. is the max change in body temperature from baseline (100 min prior to injection) over the time monitored post injection (400 min). N=7-8/group p>0.05 ttest. that 1mg/kg AM841 had no effect in CB 1 -/-mice, whereas motility was reduced in both wildtype and CB 2 -/-mice to a similar extent. N=5-11/group. *p<0.05,***p<0. 
